UC Irvine Researchers Discover Fatty Acid Treatment That Reverses Age-Related Vision Loss
Key Takeaways
- ▸A specific polyunsaturated fatty acid successfully reversed age-related vision loss in mice, offering a potential new therapeutic approach
- ▸The ELOVL2 gene emerges as a major aging marker; genetic variants in this gene are linked to faster AMD progression and could enable risk stratification
- ▸Direct fatty acid supplementation proved more effective than DHA alone, establishing a new mechanism for combating lipid metabolism changes associated with aging
Summary
Researchers at UC Irvine have identified a polyunsaturated fatty acid that can reverse age-related vision decline in mice, offering potential new treatments for conditions like age-related macular degeneration (AMD). The study, published in Science Translational Medicine, builds on earlier research into the ELOVL2 gene—a recognized aging marker—and demonstrates that supplementing the eye with specific fatty acids can restore visual function without relying on the ELOVL2 enzyme itself.
The research reveals that as the body ages, levels of very-long-chain polyunsaturated fatty acids (VLC-PUFAs) in the retina decline, leading to worsening vision and increased AMD risk. By directly injecting older mice with a specific polyunsaturated fatty acid, the team observed significant improvements in visual performance and confirmed molecular-level reversal of aging features in the eye.
Beyond therapeutic implications, the researchers also identified genetic variants in ELOVL2 associated with faster AMD progression, potentially enabling early identification of people at higher risk for vision loss. This discovery positions ELOVL2 as one of the top aging genes and could lead to more targeted, preventative treatments for vision decline.
- The research paves the way for lipid injection therapies and earlier interventions to prevent serious vision decline in aging populations
Editorial Opinion
This research represents a meaningful advance in understanding the molecular basis of age-related vision loss and offers concrete evidence that aging-related decline in the eye may be reversible through targeted metabolic intervention. The finding that a specific fatty acid outperforms DHA—long promoted for eye health—could reshape clinical approaches to AMD prevention. While the current results are limited to animal models, the identification of ELOVL2 genetic variants for risk prediction combined with a mechanistic understanding of fatty acid supplementation suggests a genuine pathway toward therapeutic translation.
